Studies produced by a suspected paper mill are frequently cited in patents, clinical guidelines and policy documents, according to a new analysis.
The work, posted on arXiv on August 31, examined the fate of nearly 2,000 academic papers with one common factor: At least one coauthor lists the Pharmakon Neuroscience Network (PNN) as an institutional affiliation.
But there’s one problem: the PNN is not a real network of scientists. Instead, it’s an authorship-for-sale scheme, as Retraction Watch reported in 2022.
Continue reading Paper mill studies get cited by clinical guidelines, policy docs and more, analysis finds








